Clinical verification of the efficacy of Pyrotinib/Areni Tablets

Pyrotinib Maleate (Pyrotinib Maleate) is a new oral irreversible tyrosine kinase inhibitor, mainly used for the treatment of advanced HER2-positive breast cancer . The drug irreversibly binds to the ATP binding sites of HER1, HER2 and HER4 in the HER family receptors, blocking key intracellular signaling pathways, including the PI3K/AKT and MAPK pathways, thereby inhibiting the proliferation and survival of tumor cells. This mechanism allows pyrotinib to display significant anti-tumor activity in a variety of HER2-positive tumor cells, providing a new treatment option for patients who cannot tolerate or are not suitable for other targeted therapies.

Clinical trial data show that pyrotinib has achieved impressive efficacy in second-line and above patients with HER2-positive advanced breast cancer. In a multi-center clinical study in China, pyrotinib combined with chemotherapy showed higher progression-free survival and overall response rate than chemotherapy alone. At the same time, in some patients, it also showed rapid tumor shrinkage and long-lasting efficacy. These results provide a scientific basis for clinical recommendation of pyrotinib, and it has also been listed as a second-line treatment option with 2A evidence level by the Chinese Society of Clinical Oncology (CSCO).

Compared with traditional targeted drugs, the advantage of pyrotinib lies in its irreversible inhibitory properties, which can block the HER signaling pathway for a longer period of time and reduce the development of drug resistance in tumor cells. This feature makes it particularly clinically valuable in patients with advanced and refractory HER2-positive breast cancer. At the same time, the convenience of oral administration of pyrotinib also provides patients with higher compliance for long-term maintenance treatment. Overseas studies and real-world data also show that pyrotinib can maintain consistent efficacy in different baseline populations. Regardless of differences in age, previous treatment history, or tumor load, its efficacy is reproducible and reliable.

In general, pyrotinib/Ereni tablets have become an important second-line treatment option for patients with HER2-positive advanced breast cancer due to its irreversible multi-target mechanism, significant clinical efficacy and good tolerability.

Reference materials:https://www.oncology-central.com/a-retrospective-real-world-study-of-pyrotinib-in-her-2-positive-advanced-breast-cancer/